AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Guided Therapeutics, Inc.

$0.25 -$0.29 (-53.70%)
OTC · 11 Sep 2026 20:00 UTC
Previous Close
$0.25
Day Range
$0.19$0.25
Year Range
$0.15$0.54
Market Cap
24.13M
AVG Volume
12.3K
Trailing/Forward PE
-6.25/-
PEG ratio
-2.63
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (USD) · TTM
0200K400K600K800K24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q2650K
26 Q1767K
25 Q4767K
25 Q3178K
25 Q2118K
25 Q11K
24 Q47K
24 Q338K
24 Q238K
24 Q182K
Net Income (USD) · TTM
-4M-3M-2M-1M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-3.73M
26 Q1-3.93M
25 Q4-3.35M
25 Q3-2.63M
25 Q2-2.54M
25 Q1-2.44M
24 Q4-2.42M
24 Q3-2.15M
24 Q2-2.17M
24 Q1-3.02M
Operating Income (USD) · TTM
-3M-2M-1M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-2.19M
26 Q1-2.48M
25 Q4-2.37M
25 Q3-2.19M
25 Q2-2.27M
25 Q1-2.16M
24 Q4-2.11M
24 Q3-2.06M
24 Q2-2.12M
24 Q1-2.97M
EBITDA (USD) · TTM
-3M-2M-1M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-2.54M
26 Q1-2.71M
25 Q4-2.47M
25 Q3-1.96M
25 Q2-1.9M
25 Q1-1.88M
24 Q4-1.94M
24 Q3-1.74M
24 Q2-1.8M
24 Q1-2.66M
Cash Flows (USD) · TTM
-2M-1.5M-1M-500K024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-1.51M
26 Q1-1.36M
25 Q4-1.07M
25 Q3-1.11M
25 Q2-1.3M
25 Q1-1.35M
24 Q4-1.12M
24 Q3-1.12M
24 Q2-1.12M
24 Q1-1.35M
EPS (USD) · TTM
-0.06-0.04-0.02024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-0.04
26 Q1-0.04
25 Q4-0.04
25 Q3-0.04
25 Q2-0.04
25 Q1-0.04
24 Q4-0.05
24 Q3-0.04
24 Q2-0.04
24 Q1-0.06
Expenses (USD) · TTM
01M2M3M4MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q22.69M
26 Q13.05M
25 Q42.94M
25 Q32.31M
25 Q22.35M
25 Q12.16M
24 Q42.11M
24 Q32.08M
24 Q22.14M
24 Q13M
Shares Outstanding (USD) · TTM
-1.5M-1M-500K0Buybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GTHP Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2-126K
26 Q1-426K
25 Q4-377K
25 Q3-339K
25 Q2-390K
25 Q1-109K
24 Q4-120K
24 Q3-79K
24 Q2-183K
24 Q1-1.27M
Employee Count
0510152016201720182019202020212022202320242025
GTHP Employee Count by quarter
PeriodEmployee Count
20253
20244
20234
20226
20215
20206
20198
20189
20179
201613
PE Ratio
05101520med 11.8Aug 21Oct 21Nov 21Dec 21Jan 22Feb 22Mar 22
GTHP PE Ratio by quarter
PeriodPE Ratio
Mar 2215.07
Mar 2210.84
Mar 2211.91
Mar 2211.52
Feb 2211.69
Feb 2213.53
Feb 2213.71
Feb 2214.33
Jan 2215.28
Jan 2215.48
Jan 2213.48
Jan 2215.28
Dec 2113.03
Dec 2114.61
Dec 2113.51
Dec 2113.88
Dec 2115.05
Nov 2114.38
Nov 2114.16
Nov 213.6
Nov 213.16
Oct 213.6
Oct 213.46
Oct 213.41
Oct 213.85
Oct 213.88
Sep 213.91
Sep 213.69
Sep 213.47
Sep 213.25
Aug 213.09
Aug 213.41
Free Cash Flow Yield
-30%-20%-10%0%med -6.99%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
GTHP Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-6.24%
Sep 26-7.8%
Aug 26-6.72%
Aug 26-5.78%
Aug 26-6.5%
Aug 26-5.26%
Jul 26-5.09%
Jul 26-5.87%
Jul 26-5.45%
Jul 26-5.09%
Jul 26-5.45%
Jun 26-6.36%
Jun 26-5.26%
Jun 26-7.52%
Jun 26-7.63%
May 26-6.67%
May 26-8.48%
May 26-7.63%
May 26-6.82%
May 26-5.8%
Apr 26-6.82%
Apr 26-6.82%
Apr 26-6.26%
Apr 26-5.69%
Mar 26-6.82%
Mar 26-5.04%
Mar 26-4.82%
Mar 26-4.53%
Feb 26-3.68%
Feb 26-3.4%
Feb 26-4.25%
Feb 26-3.4%
Jan 26-2.73%
Jan 26-3.49%
Jan 26-3.49%
Jan 26-3.13%
Jan 26-2.52%
Dec 25-3.78%
Dec 25-3.89%
Dec 25-5.04%
Dec 25-5.44%
Nov 25-5.44%
Nov 25-5.44%
Nov 25-8.5%
Nov 25-6.62%
Oct 25-6.13%
Oct 25-5.91%
Oct 25-7.19%
Oct 25-5.91%
Oct 25-6.92%
Sep 25-6.9%
Sep 25-5.91%
Sep 25-6.04%
Sep 25-5.91%
Aug 25-5.92%
Aug 25-6.3%
Aug 25-6.02%
Aug 25-14.01%
Aug 25-7.91%
Jul 25-7.91%
Jul 25-7.91%
Jul 25-7.6%
Jul 25-7.43%
Jun 25-7.06%
Jun 25-8.59%
Jun 25-10.4%
Jun 25-11.87%
May 25-14.12%
May 25-14.12%
May 25-15.81%
May 25-19.52%
May 25-18.59%
Apr 25-17.9%
Apr 25-20.33%
Apr 25-19.54%
Apr 25-23.51%
Mar 25-19.69%
Mar 25-19.79%
Mar 25-19.79%
Mar 25-20.51%
Feb 25-17.58%
Feb 25-14.8%
Feb 25-16.41%
Feb 25-16.01%
Jan 25-15.14%
Jan 25-15.36%
Jan 25-14.48%
Jan 25-13.77%
Jan 25-12.31%
Dec 24-13.01%
Dec 24-15.5%
Dec 24-11.33%
Dec 24-11.51%
Nov 24-10.36%
Nov 24-10.64%
Nov 24-11.58%
Nov 24-10.29%
Nov 24-12.54%
Oct 24-11.46%
Oct 24-13.37%
Price to Sales
05000100001500020000med 180.26Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
GTHP Price to Sales by quarter
PeriodPrice to Sales
Sep 2637.13
Sep 2629.7
Aug 2634.46
Aug 2640.1
Aug 2635.64
Aug 2633.59
Jul 2634.75
Jul 2630.11
Jul 2632.43
Jul 2634.75
Jul 2632.43
Jun 2627.8
Jun 2633.59
Jun 2623.51
Jun 2623.16
May 2626.52
May 2620.85
May 2623.16
May 2620.45
May 2624.04
Apr 2620.45
Apr 2620.45
Apr 2622.29
Apr 2624.54
Mar 2691.56
Mar 26123.91
Mar 26129.52
Mar 26137.68
Feb 26169.8
Feb 26183.57
Feb 26146.86
Feb 26183.57
Jan 26228.55
Jan 26178.98
Jan 26178.98
Jan 26199.58
Jan 26247.82
Dec 25165.21
Dec 25160.62
Dec 25123.91
Dec 25114.73
Nov 25114.73
Nov 25114.73
Nov 2573.43
Nov 25167.03
Oct 25180.39
Oct 25187.07
Oct 25153.73
Oct 25187.07
Oct 25159.85
Sep 25160.35
Sep 25187.07
Sep 25183.06
Sep 25187.07
Aug 25186.74
Aug 25175.65
Aug 25183.73
Aug 259634.49
Aug 2517072.75
Jul 2517072.75
Jul 2517072.75
Jul 2517755.66
Jul 2518165.41
Jun 2519121.48
Jun 2515706.93
Jun 2512975.29
Jun 2511377.28
May 259560.74
May 259560.74
May 258536.38
May 25819.13
May 25860.09
Apr 25892.85
Apr 25786.36
Apr 25818.31
Apr 25679.88
Mar 25150.1
Mar 25149.35
Mar 25149.35
Mar 25144.1
Feb 25168.11
Feb 25199.64
Feb 25180.12
Feb 25184.63
Jan 25195.13
Jan 25192.43
Jan 25204.14
Jan 25214.65
Jan 25240.16
Dec 24227.09
Dec 24190.63
Dec 24260.8
Dec 24256.68
Nov 24285.19
Nov 24277.69
Nov 24255.17
Nov 24287.3
Nov 24235.72
Oct 24257.83
Oct 24221
EV/EBITDA
0255075100med 3.82Apr 21Sep 21Oct 21Dec 21Feb 22Mar 22May 22
GTHP EV/EBITDA by quarter
PeriodEV/EBITDA
May 2272.42
May 2263.3
Apr 2279.51
Apr 2290.65
Apr 2278.49
Apr 2282.54
Apr 2280.52
Mar 224.08
Mar 223.17
Mar 223.4
Mar 223.32
Feb 223.35
Feb 223.75
Feb 223.79
Feb 223.92
Jan 224.12
Jan 224.17
Jan 223.74
Jan 224.12
Dec 213.64
Dec 213.98
Dec 213.74
Dec 213.82
Dec 214.08
Nov 213.93
Nov 213.88
Nov 212.41
Nov 212.18
Oct 212.41
Oct 212.34
Oct 212.31
Oct 212.55
Oct 212.56
Sep 212.58
Sep 212.46
Sep 212.35
Sep 212.23
Aug 212.15
Aug 212.32
May 2116.55
May 2117.89
Apr 2118.13
Apr 2116.51
Apr 2117.89
Apr 2117.48
Price to Book
510152025med 18.03May 25May 25Jun 25Jun 25Jul 25Jul 25Aug 25
GTHP Price to Book by quarter
PeriodPrice to Book
Aug 2511.06
Aug 2519.6
Jul 2519.6
Jul 2519.6
Jul 2520.39
Jul 2520.86
Jun 2521.95
Jun 2518.03
Jun 2514.9
Jun 2513.06
May 2510.98
May 2510.98
May 259.8
Guided Therapeutics, Inc.
GTHP
Stockpicker

Video analysis: GTHP

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: GTHP

Guided Therapeutics Reaches Collaborative Agreement with Türkiye's Ministry of Health to Become Primary Screening Test for Cervical Cancer

businesswire.com · 9 Sep 2026

Guided Therapeutics Reaches Collaborative Agreement with Türkiye's Ministry of Health to Become Primary Screening Test for Cervical Cancer

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTC:QB GTHP), the maker of the LuViva Advanced Cervical Scan, announced that it has reached an agreement with the Ministry of Health to co-develop LuViva for primary screening of cervical cancer in Türkiye. The first step of the collaborative agreement is to conduct an 800 patient clinical study to optimize LuViva's AI pattern recognition algorithms for real time detection of cellular changes that occur in the earliest stages of.

Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor

gurufocus.com · 22 Jul 2026

Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor

Guided Therapeutics, Inc. (OTC: QB GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a payment of $80,000 from distrib

Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor

businesswire.com · 22 Jul 2026

Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTC:QB GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a payment of $80,000 from distribution partner Hangzhou Dongye Medical Technology Company Ltd (HDMT). The payment is the fourth installment of a $700,000 purchase order the Company received from HDMT last year. The four LuViva devices are expected to ship later this year, which will bring the total number of devices shipped to ele.

Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA

gurufocus.com · 16 Jun 2026

Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection ba

Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA

businesswire.com · 16 Jun 2026

Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced today it had filed the results of its multicenter clinical trial with the U.S. Food and Drug Administration (FDA). The study protocol was developed through interactions with FDA and enrolled 480 women referred to biopsy because of abnormal Pap a.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.